Pharmaceutical development of IPI-504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer

Autor: John Lee, Roger H. Pak, Louis Grenier, Vince Ammoscato, Michael Curtis, Kaiming Li, John Henderson, Matthew Campbell, Denise Mayes, Jason Kropp, Natalie Goltz, Bennett Carter, Johan Sebastian Basuki, Bradley Maurer, Gary Baker, James R. Wright, David Rusch, Rebecca Ahn, Brian C. Austad, Kris Depew, Joseph Helble, Jie Ge, Jason J. Piotrowski, Marlene R. Booth, Julian Adams, Mark Douglas, Steven G. Wong, Laila Kott, James R. Porter, Geoff E. Sylvester, Dumitru Ionescu, Jennifer R. Porter, Brendan Arsenault

Publikováno v: Drug Development Research. 71:429-438

IPI-504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. IPI-504 is an aqueous soluble (>200 mg/ml) hydroquinone hydrochloride salt of 17-(allylamino)-17-demethoxygeldanam

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1542e76e86b5ffd5bfe160834ae9e695
https://doi.org/10.1002/ddr.20383

RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription.

Autor: Baranello L; Laboratory of Pathology, NCI/NIH, Bethesda, MD 20892, USA., Wojtowicz D; Computational Biology Branch, NCBI/NIH, Bethesda, MD 20892, USA., Cui K; Systems Biology Center, NHLBI/NIH, Bethesda, MD 20892, USA., Devaiah BN; Experimental Immunology Branch, NCI/NIH, Bethesda, MD 20892, USA., Chung HJ; Laboratory of Pathology, NCI/NIH, Bethesda, MD 20892, USA., Chan-Salis KY; Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802, USA., Guha R; Division of Preclinical Innovation, NCATS/NIH, Rockville, MD 20850, USA., Wilson K; Division of Preclinical Innovation, NCATS/NIH, Rockville, MD 20850, USA., Zhang X; Division of Preclinical Innovation, NCATS/NIH, Rockville, MD 20850, USA., Zhang H; Development Therapeutics Branch and Laboratory of Molecular Pharmacology, NCI/NIH, Bethesda, MD 20892, USA., Piotrowski J; Lymphoid Malignancies Branch, NCI/NIH, Bethesda, MD 20892, USA., Thomas CJ; Division of Preclinical Innovation, NCATS/NIH, Rockville, MD 20850, USA., Singer DS; Experimental Immunology Branch, NCI/NIH, Bethesda, MD 20892, USA., Pugh BF; Department of Biochemistry and Molecular Biology, Pennsylvania State University, University Park, PA 16802, USA., Pommier Y; Development Therapeutics Branch and Laboratory of Molecular Pharmacology, NCI/NIH, Bethesda, MD 20892, USA., Przytycka TM; Computational Biology Branch, NCBI/NIH, Bethesda, MD 20892, USA., Kouzine F; Laboratory of Pathology, NCI/NIH, Bethesda, MD 20892, USA., Lewis BA; Lymphoid Malignancies Branch, NCI/NIH, Bethesda, MD 20892, USA., Zhao K; Systems Biology Center, NHLBI/NIH, Bethesda, MD 20892, USA. Electronic address: zhaok@nhlbi.nih.gov., Levens D; Laboratory of Pathology, NCI/NIH, Bethesda, MD 20892, USA. Electronic address: levens@helix.nih.gov.

Publikováno v: Cell [Cell] 2016 Apr 07; Vol. 165 (2), pp. 357-71.

Metal-catalyzed oxidation of the Werner syndrome protein causes loss of catalytic activities and impaired protein-protein interactions.

Autor: Harrigan JA; Laboratory of Molecular Gerontology, NIA, National Institutes of Health, Baltimore, Maryland 21224, USA., Piotrowski J, Di Noto L, Levine RL, Bohr VA

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2007 Dec 14; Vol. 282 (50), pp. 36403-11. Date of Electronic Publication: 2007 Oct 02.

Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein.

Autor: von Kobbe C; Laboratory of Molecular Gerontology, National Institute on Aging, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224, USA., Harrigan JA, Schreiber V, Stiegler P, Piotrowski J, Dawut L, Bohr VA

Publikováno v: Nucleic acids research [Nucleic Acids Res] 2004 Aug 03; Vol. 32 (13), pp. 4003-14. Date of Electronic Publication: 2004 Aug 03 (Print Publication: 2004).